Parametric Portfolio Associates LLC decreased its position in Amneal Pharmaceuticals Inc (NYSE:AMRX) by 64.7% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 29,520 shares of the company’s stock after selling 54,139 shares during the period. Parametric Portfolio Associates LLC’s holdings in Amneal Pharmaceuticals were worth $212,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Bank of Montreal Can raised its holdings in shares of Amneal Pharmaceuticals by 87.5% in the 2nd quarter. Bank of Montreal Can now owns 8,475 shares of the company’s stock worth $60,000 after buying an additional 3,954 shares in the last quarter. Fox Run Management L.L.C. acquired a new position in shares of Amneal Pharmaceuticals in the 2nd quarter worth approximately $177,000. Atria Investments LLC acquired a new position in shares of Amneal Pharmaceuticals in the 2nd quarter worth approximately $240,000. Appleton Partners Inc. MA acquired a new position in shares of Amneal Pharmaceuticals in the 2nd quarter worth approximately $254,000. Finally, Acadian Asset Management LLC raised its holdings in shares of Amneal Pharmaceuticals by 96.3% in the 2nd quarter. Acadian Asset Management LLC now owns 45,000 shares of the company’s stock worth $323,000 after buying an additional 22,073 shares in the last quarter. 35.01% of the stock is owned by hedge funds and other institutional investors.
AMRX traded up $0.08 during mid-day trading on Friday, reaching $2.73. The stock had a trading volume of 1,423,435 shares, compared to its average volume of 1,461,225. The stock has a market capitalization of $792.59 million, a P/E ratio of 2.87, a P/E/G ratio of 0.99 and a beta of 1.48. The company has a debt-to-equity ratio of 3.66, a quick ratio of 1.41 and a current ratio of 2.17. The firm’s fifty day simple moving average is $3.10 and its two-hundred day simple moving average is $5.39. Amneal Pharmaceuticals Inc has a 52 week low of $2.27 and a 52 week high of $20.40.
Amneal Pharmaceuticals (NYSE:AMRX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.04 EPS for the quarter, missing the Zacks’ consensus estimate of $0.13 by ($0.09). The firm had revenue of $378.30 million during the quarter, compared to the consensus estimate of $403.90 million. Amneal Pharmaceuticals had a negative net margin of 3.65% and a positive return on equity of 28.20%. The firm’s quarterly revenue was down 20.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.28 earnings per share. As a group, analysts expect that Amneal Pharmaceuticals Inc will post 0.31 EPS for the current fiscal year.
A number of research firms recently commented on AMRX. Zacks Investment Research lowered Amneal Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 23rd. Leerink Swann lowered Amneal Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday. SunTrust Banks restated a “buy” rating and set a $5.00 price target on shares of Amneal Pharmaceuticals in a research report on Tuesday, August 6th. Svb Leerink lowered Amneal Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday. Finally, BMO Capital Markets decreased their price target on Amneal Pharmaceuticals from $6.00 to $5.00 and set a “market perform” rating on the stock in a research report on Tuesday, August 6th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the stock. Amneal Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $8.59.
In related news, SVP Pradeep Bhadauria purchased 30,000 shares of the business’s stock in a transaction dated Friday, August 16th. The shares were bought at an average price of $2.41 per share, with a total value of $72,300.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Ted C. Nark purchased 50,000 shares of the business’s stock in a transaction dated Wednesday, August 28th. The stock was bought at an average cost of $2.39 per share, for a total transaction of $119,500.00. The disclosure for this purchase can be found here. 25.92% of the stock is currently owned by company insiders.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
Featured Story: Bid-Ask Spread
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.